Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis

BACKGROUND: New coronavirus disease 2019 (COVID-19) medications force decision-makers to weigh limited evidence of efficacy and cost in determining which patient populations to target for treatment. A case in point is nirmatrelvir/ritonavir, a drug that has been recommended for elderly, high-risk in...

Descripción completa

Detalles Bibliográficos
Autores principales: Savinkina, Alexandra, Paltiel, A David, Ross, Joseph S, Gonsalves, Gregg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792084/
https://www.ncbi.nlm.nih.gov/pubmed/36589482
http://dx.doi.org/10.1093/ofid/ofac637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792084/
https://www.ncbi.nlm.nih.gov/pubmed/36589482
http://dx.doi.org/10.1093/ofid/ofac637

Ejemplares similares